A Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive, Rufinamide Treatment in Pediatric Subjects 1 to Less than 4 Years of Age

Grants and Contracts Details

StatusFinished
Effective start/end date6/14/11 → 6/30/15

Funding

  • Eisai Incorporated: $28,259.00